Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape

Journal of Immunology

Volumn 193, Issue 2, 2014, Pages 783-796

  Zhao, Yinglan ^a   Ren, Yushan ^a   Zhang, Xuping ^a   Zhao, Ping ^b   Tao, Wanyin ^c   Zhong, Jin ^c   Li, Qiao ^d   Zhang, Xiao Lian ^a  

^a WUHAN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c INSTITUTE PASTEUR OF SHANGHAI   (China)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CD81 ANTIGEN; CLAUDIN 1; FIBRINOGEN; FICOLIN; FICOLIN 2; GLYCOPROTEIN E1; GLYCOPROTEIN E2; LOW DENSITY LIPOPROTEIN RECEPTOR; OCCLUDIN; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS PARTICLE;

ANTIGENS, CD81; APOLIPOPROTEIN E3; BINDING, COMPETITIVE; BLOTTING, WESTERN; CELL LINE, TUMOR; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HELA CELLS; HEPACIVIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; LECTINS; MANNANS; MICROSCOPY, CONFOCAL; POLYSACCHARIDES; PROTEIN BINDING; RECEPTORS, LDL; RNA INTERFERENCE; SCAVENGER RECEPTORS, CLASS B; TUMOR ESCAPE; VIRAL ENVELOPE PROTEINS;

EID: 84904262489     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302563     Document Type: Article

References (51)

1. Pawlotsky, J. M. 2013. Treatment of chronic hepatitis C: current and future. Curr. Top. Microbiol. Immunol. 369: 321-342.
2. Zeisel, M. B., I. Fofana, S. Fafi-Kremer, and T. F. Baumert. 2011. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J. Hepatol. 54: 566-576.
3. Helle, F., and J. Dubuisson. 2008. Hepatitis C virus entry into host cells. Cell. Mol. Life Sci. 65: 100-112. (Pubitemid 351152228)
4. Lindenbach, B. D., and C. M. Rice. 2013. The ins and outs of hepatitis C virus entry and assembly. Nat. Rev. Microbiol. 11: 688-700.
5. Barth, H., E. K. Schnober, F. Zhang, R. J. Linhardt, E. Depla, B. Boson, F. L. Cosset, A. H. Patel, H. E. Blum, and T. F. Baumert. 2006. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J. Virol. 80: 10579-10590. (Pubitemid 44628904)
6. Owen, D. M., H. Huang, J. Ye, and M. Gale, Jr. 2009. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 394: 99-108.
7. Catanese, M. T., H. Ansuini, R. Graziani, T. Huby, M. Moreau, J. K. Ball, G. Paonessa, C. M. Rice, R. Cortese, A. Vitelli, and A. Nicosia. 2010. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J. Virol. 84: 34-43.
8. Falkowska, E., F. Kajumo, E. Garcia, J. Reinus, and T. Dragic. 2007. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J. Virol. 81: 8072-8079. (Pubitemid 47101493)
9. Brazzoli, M., A. Bianchi, S. Filippini, A. Weiner, Q. Zhu, M. Pizza, and S. Crotta. 2008. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J. Virol. 82: 8316-8329.
10. Evans, M. J., T. von Hahn, D. M. Tscherne, A. J. Syder, M. Panis, B. Wölk, T. Hatziioannou, J. A. McKeating, P. D. Bieniasz, and C. M. Rice. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446: 801-805. (Pubitemid 46582027)
11. Ploss, A., M. J. Evans, V. A. Gaysinskaya, M. Panis, H. You, Y. P. de Jong, and C. M. Rice. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457: 882-886.
12. Benedicto, I., F. Molina-Jiménez, B. Bartosch, F. L. Cosset, D. Lavillette, J. Prieto, R. Moreno-Otero, A. Valenzuela-Fernández, R. Aldabe, M. López-Cabrera, and P. L. Majano. 2009. The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J. Virol. 83: 8012-8020.
13. Cocquerel, L., C. Voisset, and J. Dubuisson. 2006. Hepatitis C virus entry: potential receptors and their biological functions. J. Gen. Virol. 87: 1075-1084.
14. Albecka, A., S. Belouzard, A. Op de Beeck, V. Descamps, L. Goueslain, J. Bertrand-Michel, F. Tercé, G. Duverlie, Y. Rouillé, and J. Dubuisson. 2012. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 55: 998-1007.
15. Garlatti, V., L. Martin, M. Lacroix, E. Gout, G. J. Arlaud, N. M. Thielens, and C. Gaboriaud. 2010. Structural insights into the recognition properties of human ficolins. J. Innate Immun. 2: 17-23.
16. Fujita, T. 2002. Evolution of the lectin-complement pathway and its role in innate immunity. Nat. Rev. Immunol. 2: 346-353. (Pubitemid 37328757)
17. Fujita, T., M. Matsushita, and Y. Endo. 2004. The lectin-complement pathway: its role in innate immunity and evolution. Immunol. Rev. 198: 185-202. (Pubitemid 38406944)
18. Liu, J., M. A. Ali, Y. Shi, Y. Zhao, F. Luo, J. Yu, T. Xiang, J. Tang, D. Li, Q. Hu, et al. 2009. Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell. Mol. Immunol. 6: 235-244.
19. Willnow, T. E. 1999. The low-density lipoprotein receptor gene family: multiple roles in lipid metabolism. J. Mol. Med. 77: 306-315. (Pubitemid 29144066)
20. Mahley, R. W., and S. C. Rall, Jr. 2000. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1: 507-537.
21. André, P., F. Komurian-Pradel, S. Deforges, M. Perret, J. L. Berland, M. Sodoyer, S. Pol, C. Bréchot, G. Paranhos-Baccalà, and V. Lotteau. 2002. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 76: 6919-6928.
22. Chang, K. S., J. Jiang, Z. Cai, and G. Luo. 2007. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J. Virol. 81: 13783-13793. (Pubitemid 350247871)
23. Hishiki, T., Y. Shimizu, R. Tobita, K. Sugiyama, K. Ogawa, K. Funami, Y. Ohsaki, T. Fujimoto, H. Takaku, T. Wakita, et al. 2010. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J. Virol. 84: 12048-12057.
24. Chen, F., Y. Hu, D. Li, H. Chen, and X. L. Zhang. 2009. CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2. PLoS ONE 4: e8142.
25. Li, P., Q. Wan, Y. Feng, M. Liu, J. Wu, X. Chen, and X. L. Zhang. 2007. Engineering of N-glycosylation of hepatitis C virus envelope protein E2 enhances T cell responses for DNA immunization. Vaccine 25: 1544-1551. (Pubitemid 46074287)
26. Yang, J. H., J. P. Lai, S. D. Douglas, D. Metzger, X. H. Zhu, and W. Z. Ho. 2002. Real-time RT-PCR for quantitation of hepatitis C virus RNA. J. Virol. Methods 102: 119-128. (Pubitemid 34185477)
27. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 102: 9294-9299. (Pubitemid 40923557)
28. Benga, W. J., S. E. Krieger, M. Dimitrova, M. B. Zeisel, M. Parnot, J. Lupberger, E. Hildt, G. Luo, J. McLauchlan, T. F. Baumert, and C. Schuster. 2010. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology 51: 43-53.
29. Chen, F., Y. Zhao, M. Liu, D. Li, H. Wu, H. Chen, Y. Zhu, F. Luo, J. Zhong, Y. Zhou, et al. 2010. Functional selection of hepatitis C virus envelope E2-binding peptide ligands by using ribosome display. Antimicrob. Agents Chemother. 54: 3355-3364.
30. Tong, Y., Y. Zhu, X. Xia, Y. Liu, Y. Feng, X. Hua, Z. Chen, H. Ding, L. Gao, Y. Wang, et al. 2011. Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J. Virol. 85: 2793-2802.
31. + lymphocytes from asthmatics with or without depression. PLoS ONE 7: e48367.
32. Jiang, J., and G. Luo. 2009. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J. Virol. 83: 12680-12691.
33. Liu, S., W. Yang, L. Shen, J. R. Turner, C. B. Coyne, and T. Wang. 2009. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 83: 2011-2014.
34. Keck, Z. Y., J. Xia, Y. Wang, W. Wang, T. Krey, J. Prentoe, T. Carlsen, A. Y. Li, A. H. Patel, S. M. Lemon, et al. 2012. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog. 8: e1002653.
35. Arold, S., P. Sullivan, T. Bilousova, E. Teng, C. A. Miller, W. W. Poon, H. V. Vinters, L. B. Cornwell, T. Saing, G. M. Cole, and K. H. Gylys. 2012. Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex. Acta Neuropathol. 123: 39-52.
36. Hueging, K., M. Doepke, G. Vieyres, D. Bankwitz, A. Frentzen, J. Doerrbecker, F. Gumz, S. Haid, B. Wölk, L. Kaderali, and T. Pietschmann. 2014. Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. J. Virol. 88: 1433-1446.
37. Yang, W., C. Qiu, N. Biswas, J. Jin, S. C. Watkins, R. C. Montelaro, C. B. Coyne, and T. Wang. 2008. Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. J. Biol. Chem. 283: 8643-8653.
38. Koutsoudakis, G., E. Herrmann, S. Kallis, R. Bartenschlager, and T. Pietschmann. 2007. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J. Virol. 81: 588-598. (Pubitemid 46067886)
39. Burlone, M. E., and A. Budkowska. 2009. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J. Gen. Virol. 90: 1055-1070.
40. Hu, Y. L., F. L. Luo, J. L. Fu, T. L. Chen, S. M.Wu, Y. D. Zhou, and X. L. Zhang. 2013. Early increased ficolin-2 concentrations are associated with severity of liver inflammation and efficacy of anti-viral therapy in chronic hepatitis C patients. Scand. J. Immunol. 77: 144-150.
41. Motulsky, H., and A. Chistopoulos. 2004. Fitting Models to Biological Data Using Linear and Nonlinear Regression. A Practical Guide to Curve Fitting. Oxford University Press, New York.
42. Graham, J. C., and H. Zarbl. 2012. Use of cell-SELEX to generate DNA aptamers as molecular probes of HPV-associated cervical cancer cells. PLoS ONE 7: e36103.
43. Heathcote, J., and J. Main. 2005. Treatment of hepatitis C. J. Viral Hepat. 12: 223-235. (Pubitemid 40638030)
44. Meuleman, P., A. Albecka, S. Belouzard, K. Vercauteren, L. Verhoye, C. Wychowski, G. Leroux-Roels, K. E. Palmer, and J. Dubuisson. 2011. Griffithsin has antiviral activity against hepatitis C virus. Antimicrob. Agents Chemother. 55: 5159-5167.
45. Helle, F., C. Wychowski, N. Vu-Dac, K. R. Gustafson, C. Voisset, and J. Dubuisson. 2006. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J. Biol. Chem. 281: 25177-25183. (Pubitemid 44401904)
46. Scherzer, T. M., K. Staufer, G. Novacek, P. Steindl-Munda, S. Schumacher, H. Hofer, P. Ferenci, and H. Vogelsang. 2008. Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C. Aliment. Pharmacol. Ther. 28: 742-748.
47. Iacob, R. E., I. Perdivara, M. Przybylski, and K. B. Tomer. 2008. Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans. J. Am. Soc. Mass Spectrom. 19: 428-444.
48. Sainz, B., Jr., N. Barretto, D. N. Martin, N. Hiraga, M. Imamura, S. Hussain, K. A. Marsh, X. Yu, K. Chayama, W. A. Alrefai, and S. L. Uprichard. 2012. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 18: 281-285.
49. Price, D. A., M. F. Bassendine, S. M. Norris, C. Golding, G. L. Toms, M. L. Schmid, C. M. Morris, A. D. Burt, and P. T. Donaldson. 2006. Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut 55: 715-718.
50. Kuhlmann, I., A. M. Minihane, P. Huebbe, A. Nebel, and G. Rimbach. 2010. Apolipoprotein E genotype and hepatitis C, HIVand herpes simplex disease risk: a literature review. Lipids Health Dis. 9: 8-21.
51. Liu, C. C., T. Kanekiyo, H. Xu, and G. Bu. 2013. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9: 106-118.